Home > Neurology > Trigeminal-neuralgia

Trigeminal Neuralgia Treatment in Mumbai

It has been called the suicide disease not because it kills, but because the pain is so severe and so sudden that patients have historically felt they had no other way out. That context matters. Electric shock facial pain lasting seconds but striking dozens of times a day, triggered by eating, speaking, or a breeze against the cheek trigeminal neuralgia is one of the most intense pain conditions known to medicine.

At Shree Hospitals, we do not manage this condition lightly. Our trigeminal neuralgia treatment in Mumbai offers a clear pathway from accurate diagnosis through medical management to surgical cure because for the right patient, surgery is not a last resort. It is the answer.

(24×7 Emergency Care)

1800-268-4000

(24×7 Emergency Care)

1800-268-4000

Our Approach in Managing Trigeminal Neuralgia

Most trigeminal neuralgia patients have seen a dentist, an ENT specialist, and sometimes an ophthalmologist before a neurologist because the pain is so localised it mimics tooth pain, sinus pain, or eye pain.

Our facial pain specialist team in Mumbai, India starts by confirming the diagnosis correctly, because treatment selection depends entirely on whether this is classical, secondary, or idiopathic trigeminal neuralgia.

Accurate Diagnosis & Classification

Classical TN — caused by vascular compression of the trigeminal nerve root at the pons (most common)
Secondary TN — caused by MS, tumour, or other structural pathology affecting the nerve
Idiopathic TN — no identifiable cause on imaging despite typical clinical features
Detailed pain history — distribution (V1, V2, V3 branches), trigger identification, duration and frequency of attacks

Neuroimaging

MRI of the brain specifically to identify neurovascular contact at the trigeminal nerve root entry zone
MRI brain with gadolinium to exclude secondary causes (MS plaques, cerebellopontine angle tumour)
Results of imaging directly influence the surgical planning for microvascular decompression

Medical Management — First Line

Carbamazepine is the cornerstone of trigeminal neuralgia pharmacotherapy and remains the only drug with Level A evidence.

Carbamazepine — typically effective in early or mild-moderate disease; dose is titrated against pain control and tolerability
Oxcarbazepine — similar efficacy with a better tolerability and drug interaction profile
Lamotrigine, Baclofen, Gabapentin — adjuncts for patients with incomplete response or intolerance
Regular sodium monitoring with Carbamazepine — hyponatraemia is a common side effect, particularly in elderly patients

Microvascular Decompression (MVD) — The Definitive Surgical Option

For patients with classical TN confirmed on imaging, microvascular decompression offers the highest rates of long-term pain relief.

A microsurgical procedure through a small retromastoid incision
The offending blood vessel is identified and separated from the trigeminal nerve using a Teflon pad
Pain relief is typically immediate and post-operative
Long-term pain freedom: 70–80% at 10 years in appropriately selected patients
Not appropriate for secondary TN due to MS — different treatment pathway applies

Percutaneous Ablative Procedures

For patients who are not surgical candidates due to age, medical comorbidities, or patient preference.

Percutaneous Balloon Compression
Glycerol Rhizolysis
Radiofrequency Thermocoagulation
All carry a trade-off between pain relief and sensory numbness, fully discussed with each patient before the procedure

How to Identify Trigeminal Neuralgia?

Trigeminal neuralgia has a pattern so distinctive that the diagnosis can often be made on history alone if the right questions are asked.

Features that point clearly toward trigeminal neuralgia:

Pain that is electric, stabbing, or shock-like in quality described by almost every patient as the worst pain they have experienced
Duration of individual attacks is extremely brief seconds to two minutes but attacks recur many times a day
A specific trigger chewing, talking, brushing teeth, touching the face, cold air, or smiling
A refractory period after a trigger-induced attack, during which further stimulation does not provoke pain
Pain strictly unilateral and within the anatomical territory of one or more trigeminal nerve branches
Complete absence of pain between attacks in the early stages background pain suggests a different or evolving diagnosis

This is a cranial nerve 5 disorder that should not be managed empirically without imaging. If you have been told you have dental pain that teeth extractions haven't fixed, or sinus pain that scans haven't confirmed, or facial pain that comes and goes in electric bursts seek trigeminal neuralgia treatment in Mumbai from a team that treats this condition regularly.

Important FAQs: Trigeminal Neuralgia

Is trigeminal neuralgia life-threatening?

Not directly. However, the severity of pain can prevent eating, speaking, and normal daily function, leading to significant physical and psychological deterioration without treatment.

Does trigeminal neuralgia always respond to Carbamazepine?

Initially, most patients respond well. Over time, higher doses are required and side effects accumulate. Surgical intervention is then strongly recommended, particularly if imaging confirms neurovascular contact.

What is the cure rate with microvascular decompression?

Long-term pain freedom is achieved in approximately 70–80% of patients at 10 years. It offers the best long-term outcomes of any TN treatment when correctly indicated.

Is the surgery risky?

MVD is a cranial procedure and carries small but real risks hearing loss, facial numbness, cerebellar injury, and anaesthetic risk. These are fully discussed before surgery and are significantly lower at experienced centres.

Can trigeminal neuralgia come back after surgery?

Recurrence occurs in 10–20% of patients at 10 years after MVD. It can often be managed with repeat medication or a percutaneous procedure.

What if I have MS and trigeminal neuralgia?

MS-related TN does not involve neurovascular compression — MVD is generally not indicated. Management centres on optimal MS disease control and specific pharmacotherapy. Our team assesses each case individually.